$HCLP: Here’s Why Hi-Crush Partners Fell 22.2% in November

Date: Saturday, December 8th, 2018

Stock(s) mentioned:

Source: Motley Fool (https://www.fool.com)

Summary: Shares of Hi-Crush Partners (NYSE:HCLP) fell over 22% last month, according to data from S&P Global Market Intelligence. Investors went on a pretty wild ride …

Full article address: https://www.fool.com/investing/2018/12/08/heres-why-hi-crush-partners-fell-222-in-november.aspx

Related News:

$HCLP: Why Hi-Crush Partners Units Fell 10.8% in February

$HCLP: Why Hi-Crush Partners Units Surged More Than 20% in January

$HCLP $BREW $MATX: Analysis: Positioning to Benefit within Hilton Worldwide, Kansas City …

$HCLP: Things Could Have Been a Lot Worse for Hi-Crush Partners This …

$HCLP: Hi-Crush Partners LP (HCLP) CEO Robert Rasmus on Q4 2018 …

$HCLP: Hi-Crush Partners LP (HCLP) Q4 2018 Earnings Conference Call …

$HCLP: Hi-Crush Partners +1.5% after Q4 results not as bad as expected

$HCLP: Hi-Crush Partners Q4 2018 Earnings Preview

$HCLP: Hi-Crush Announces Integrated Agreement for Northern White Frac …

$RFL $HEAR $HCLP $OZK: Midday movers and shakers

$HCLP: Hi-Crush Partners LP Announces Timing of Fourth Quarter and Full …

Latest News:

$BAC: Bank of America’s tech chief is skeptical on blockchain despite having the most patents for it

$YMM9 $ESM9 $NQM9 $SPX $COMP $DJIA: Market Snapshot: Dow futures climb as China trade talks set to resume

$MCD $NKE $RHT: Stocks to Watch: McDonald’s, Canopy Growth, Nike

$C: Citigroup Enters Banking’s Hottest Business With New Payments Unit

$DKS $GOOGL $HD $WMT: Dick’s Tech Chief Goes All Out on In-House Software

$SFTBY $MER-K $BCS $C $DB $MS: Uber Steers $3.1 Billion Careem Deal as Implied Value Gains Ahead of Planned IPO

$TTWO $NTDOY $ATVI $SNE $UBSFY $CCOEY: The Most Popular Video Games in the U.S.

$MKC: McCormick Beats Profit Estimates but Misses Slightly on Sales

$GES: Bear of the Day: Guess (GES)

$MCD $DPZ $CMG $YUM: McDonald’s Buys Dynamic Yield, Boosts Technology Offerings

$ASRT: Will Assertio Therapeutics Continue to Surge Higher?